The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis
Open accessAbstract
Cyclooxygenase-2 (COX-2), the enzyme at the rate-limiting step of prostanoid production, has been found to be overexpressed in human lung cancer. To evaluate lung tumor COX-2 modulation of antitumor immunity, we studied the antitumor effect of specific genetic or pharmacological inhibition of COX-2 in a murine Lewis lung carcinoma (3LL) model. Inhibition of COX-2 led to marked lymphocytic infiltration of the tumor and reduced tumor growth. Treatment of mice with anti-PGE2 mAb replicated the growth reduction seen in tumor-bearing mice treated with COX-2 inhibitors. COX-2 inhibition was accompanied by a significant decrement in IL-10 and a concomitant restoration of IL-12 production by APCs. Because the COX-2 metabolite PGE2 is a potent inducer of IL-10, it was hypothesized that COX-2 inhibition led to antitumor responses by down-regulating production of this potent immunosuppressive cytokine. In support of this concept, transfer of IL-10 transgenic T lymphocytes that overexpress IL-10 under control of the IL-2 promoter reversed the COX-2 inhibitor-induced antitumor response. We conclude that abrogation of COX-2 expression promotes antitumor reactivity by restoring the balance of IL-10 and IL-12 in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272 · cited 1×
“In addition, COX-2 expression in colon tumor lines enhances tumor invasiveness (26), increases metastatic potential (27), and promotes angiogenesis (28).”
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2
Smith, W. L., Garavito, R. M., & DeWitt, D. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33157 · Cited by 1,978
de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.915 · Cited by 1,930
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.10.3444 · Cited by 1,865
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
Tsujii, M., Kawano, S., & DuBois, R. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3336 · Cited by 1,398
Herschman, H. R. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00194-8 · Cited by 1,197
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Cited by
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Self-citationWang, D., & DuBois, R. N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2809 · Cited by 1,793
Regulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220
“Furthermore, in vivo studies have revealed that prevention of adenoma development in FAP patients is more effective when tissue prostaglandin levels are reduced through NSAID treatment [38], and more specifically, sequestration of PGE2 by administration of a PGE2 monoclonal antibody in mice has been demonstrated suffi…”
BackgroundWang, D. (2006) · Gut · doi:10.1136/gut.2004.047100 · Cited by 899
Hata, A. N., & Breyer, R. M. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.06.003 · Cited by 840
Cyclooxygenase 2: a molecular target for cancer prevention and treatment
Subbaramaiah, K., & Dannenberg, A. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00043-3 · Cited by 649
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
Rodriguez, P. C., Hernandez, C. P., Quiceno, D., Dubinett, S. M., Zabaleta, J., Ochoa, J. B., Gilbert, J., & Ochoa, A. C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050715 · Cited by 609
Self-citationHeger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells
Baratelli, F., Lin, Y., Zhu, L., Yang, S.-C., Heuzé-Vourc’h, N., Zeng, G., Reckamp, K., Dohadwala, M., Sharma, S., & Dubinett, S. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1483 · Cited by 573
Self-citationErin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer
Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., & Subbaramaiah, K. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00488-0 · Cited by 508
Sharma, S., Yang, S.-C., Zhu, L., Reckamp, K., Gardner, B., Baratelli, F., Huang, M., Batra, R. K., & Dubinett, S. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0141 · Cited by 506
Self-citationCOX-2: A Molecular Target for Colorectal Cancer Prevention
Brown, J. R., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.051 · Cited by 444
Molecular Link Mechanisms between Inflammation and Cancer
B. Vendramini-Costa, D., & E. Carvalho, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802083707 · Cited by 417
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Sionov, R. V., Fridlender, Z. G., & Granot, Z. (2015) · Cancer Microenvironment · doi:10.1007/s12307-014-0147-5 · Cited by 416
Mechanistic links between COPD and lung cancer
Houghton, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3477 · Cited by 414
Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
Dannenberg, A. J., Lippman, S. M., Mann, J. R., Subbaramaiah, K., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.112 · Cited by 404
Interleukin-10 and the immune response against cancer: a counterpoint
Mocellin, S., Marincola, F. M., & Young, H. A. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705358 · Cited by 402
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy
Gately, S., & Li, W. W. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.03.040 · Cited by 398
Harizi, H., Juzan, M., Pitard, V., Moreau, J.-F., & Gualde, N. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2255 · Cited by 384
Kaliński, P., Vieira, P. L., Schuitemaker, J. H. N., de Jong, E. C., & Kapsenberg, M. L. (2001) · Blood · doi:10.1182/blood.v97.11.3466 · Cited by 362
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Tumor-induced perturbations of cytokines and immune cell networks
Burkholder, B., Huang, R.-Y., Burgess, R., Luo, S., Jones, V. S., Zhang, W., Lv, Z.-Q., Gao, C.-Y., Wang, B.-L., Zhang, Y.-M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.004 · Cited by 356
Bengmark, S. (2006) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/014860710603000145 · Cited by 345
COX-2 as a target for cancer chemotherapy
Ghosh, N., Chaki, R., Mandal, V., & Mandal, S. C. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70262-0 · Cited by 344
Evans, J. F., Oshima, M., Murai, N., Kargman, S., Arguello, M., Luk, P., Kwong, E., & Taketo, M. M. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02780.x · Cited by 333
Inflammatory cell infiltration of tumors: Jekyll or Hyde
Talmadge, J. E., Donkor, M., & Scholar, E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9072-0 · Cited by 313
Lipoxygenase metabolism: roles in tumor progression and survival
Pidgeon, G. P., Lysaght, J., Krishnamoorthy, S., Reynolds, J. V., O’Byrne, K., Nie, D., & Honn, K. V. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9098-3 · Cited by 295
Current status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
Talmadge, J. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0182 · Cited by 285
Dohadwala, M., Yang, S.-C., Luo, J., Sharma, S., Batra, R. K., Huang, M., Lin, Y., Goodglick, L., Krysan, K., Fishbein, M. C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3635 · Cited by 282
Self-citationBenish, M., Bartal, I., Goldfarb, Y., Levi, B., Avraham, R., Raz, A., & Ben-Eliyahu, S. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9890-5 · Cited by 281
Altorki, N. K., Keresztes, R. S., Port, J. L., Libby, D. M., Korst, R. J., Flieder, D. B., Ferrara, C. A., Yankelevitz, D. F., Subbaramaiah, K., Pasmantier, M. W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.127 · Cited by 275
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Wu, A. A., Drake, V., Huang, H.-S., Chiu, S., & Zheng, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016700 · Cited by 271
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Dohadwala, M., Batra, R. K., Luo, J., Lin, Y., Krysan, K., Põld, M., Sharma, S., & Dubinett, S. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m210707200 · Cited by 260
Self-citationZhu, L. X., Sharma, S., Stolina, M., Gardner, B., Roth, M. D., Tashkin, D. P., & Dubinett, S. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.373 · Cited by 252
Self-citationDual biological effects of the cytokines interleukin-10 and interferon-γ
Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138
Sorski, L., Melamed, R., Matzner, P., Lavon, H., Shaashua, L., Rosenne, E., & Ben-Eliyahu, S. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.05.017 · Cited by 85
Sirianni, R., Chimento, A., De Luca, A., Zolea, F., Carpino, A., Rago, V., Maggiolini, M., Andò, S., & Pezzi, V. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.041020 · Cited by 41
Huniadi, C. A., Pop, O. L., Antal, T. A., & Stamatian, F. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2013.03.022 · Cited by 35
Metadata
- Authors
- Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., Lee, J. C., & Dubinett, S. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-01-01
- Volume
- 164
- Issue
- 1
- Pages
- 361-370
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2146708145
- Cited by
- 465
- References
- 61
- FWCI
- 18.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.